Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
Trevena Inc (NASDAQ: TRVN) is a clinical-stage biopharmaceutical pioneer developing novel therapies for central nervous system disorders and pain management through advanced GPCR targeting. This page provides investors and industry professionals with a comprehensive repository of Trevena news, including clinical trial updates, regulatory milestones, and research developments.
Access timely updates on Trevena's innovative pipeline, including OLINVYK™ (oliceridine) for acute pain and investigational candidates like TRV045 for neuropathic pain. Track progress across preclinical studies, FDA communications, and strategic partnerships that shape the company's trajectory in neuroscience therapeutics.
Key content includes earnings reports, patent filings, scientific presentations, and analyses of Trevena's biased ligand platform—a Nobel Prize-influenced approach to minimizing opioid-related side effects. All materials are curated to support informed decision-making without promotional bias.
Bookmark this page for centralized access to Trevena's latest advancements in non-opioid pain management and CNS disorder treatments. Regularly updated to reflect new developments in GPCR-focused drug discovery and clinical-stage biopharma innovation.
Trevena Inc (TRVN) reported Q3 2024 financial results with a net loss of $4.9 million ($5.79 per share), compared to $7.9 million in Q3 2023. The company secured a $2 million non-dilutive financing from R-Bridge Healthcare Fund, with potential for additional $8 million based on milestones. Following a 1-for-25 reverse stock split in August 2024, TRVN was delisted from Nasdaq and began trading on OTC Pink Sheets. The company implemented significant cost-cutting measures, including executive terminations, reducing to four employees, and multiple board resignations. Cash position stood at $13.5 million as of September 30, 2024.
Trevena (Nasdaq: TRVN), a biopharmaceutical company focused on CNS disorders, announced on October 4, 2024, that it received a delisting notification from the Nasdaq Hearings Panel. The delisting is due to Trevena's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1). Trading of Trevena's common stock on Nasdaq will be suspended effective October 8, 2024.
The company expects its common stock to begin trading on the Pink Open Market (pink sheets) operated by OTC Markets Group. However, Trevena cautions that there is no assurance that a broker will continue to make a market in the company's stock or that trading will continue on an over-the-counter market or elsewhere.
Trevena (Nasdaq: TRVN) has announced a 1-for-25 reverse stock split, effective August 13, 2024. This move aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company's common stock will continue trading under the symbol 'TRVN' on the Nasdaq Capital Market, with a new CUSIP number 89532E 307. The split will affect all outstanding shares, equity incentive plans, and adjust stock options and warrants. No fractional shares will be issued; instead, affected stockholders will receive cash payments. This decision follows stockholder approval at the June 13, 2024 Annual General Meeting.
Trevena Inc. (Nasdaq: TRVN) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. TRV045, their novel S1P receptor modulator for neuropathic pain and epilepsy, showed promising preclinical results with sustained long-term analgesic effects and seizure protection.
2. The company completed a $12 million financing, including a $2 million non-dilutive tranche and a $10 million reduction in liabilities.
3. Trevena continues its strategic review of OLINVYK, considering options such as sale, license, or discontinuation of US commercial sales.
4. Q2 2024 financial results showed a net loss of $4.9 million ($0.23 per share), compared to $8.0 million in Q2 2023.
5. Cash and cash equivalents stood at $16.4 million as of June 30, 2024.
Trevena (Nasdaq: TRVN) announced a $2 million non-dilutive financing tranche from R-Bridge Healthcare Fund, with potential for an additional $8 million based on OLINVYK's US commercialization milestones. The amendment also reduces Trevena's outstanding liabilities by $10 million. As part of the deal, Trevena transferred certain Chinese IP to R-Bridge, amended existing warrants to a 15% premium of current stock price, and extended their exercise period to five years. The cap on US royalties payable was increased to $12 million. Trevena had previously received $30 million in non-dilutive funding from R-Bridge.
Trevena announced promising preclinical data for its novel S1P1 receptor modulator, TRV045, in treating chronic neuropathic pain and epilepsy. In a study on chemotherapy-induced peripheral neuropathy, TRV045 exhibited long-term analgesic effects without receptor desensitization, showing superiority over fingolimod. In epilepsy models, TRV045 increased seizure thresholds in animals, but did not show significant results in preventing epilepsy onset. Further NIH studies are planned to explore its potential in seizure prevention. These findings suggest TRV045's potential to offer new therapeutic avenues in pain and epilepsy management.
Trevena reported its Q1 2024 results, with a net loss of $7.7 million and cash reserves of $23.6 million. The clinical development of TRV045, a candidate for chronic pain and epilepsy, is progressing with data expected in the second half of 2024. TRV045 has shown a favorable tolerability profile in multiple studies. Additionally, the NIH continues to explore TRV045's efficacy in epilepsy.
Strategically, Trevena is reviewing options for OLINVYK, including potential sale or discontinuation. Cost-cutting measures have resulted in annual savings of $3.5-$4 million. Trevena received an extension until August 28, 2024, to comply with Nasdaq listing requirements but faces delisting risks if compliance is not achieved.